HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q4 2021 Results - Earnings Call Transcript

Call scheduled for today, March 29, at 4:30 pm ET Call scheduled for today, March 29, at 4:30 pm ET

HTG Molecular Diagnostics Reports Full Year 2021 Results

TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to HTG from the private placement, before deducting the placement agent fees and other estimated fees and expenses related to the private placement, are expected to be approximately $7.5 million. HTG intends to use the net proceeds from the private placement for working capital and general corporate purposes.

HTG Molecular Diagnostics Announces $7.5 Million Private Placement

TUCSON, Ariz., Feb. 03, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed Robert Spitale, Ph.D., Associate Director and Associate Dean of Research in the School of Pharmacy and Pharmaceutical Services at the University of California, Irvine (UC Irvine), to the HTG Therapeutics Scientific Advisory Board.

HTG Names Renowned RNA Expert Dr. Robert Spitale to Therapeutics Scientific Advisory Board

Brings Significant Operational Experience in Building Therapeutic Drug Development Businesses Brings Significant Operational Experience in Building Therapeutic Drug Development Businesses

HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors

Preliminary full year 2021 unaudited revenue of $8.9 million

HTG Molecular Diagnostics Announces Certain Preliminary 2021 Unaudited Financial Results

Expands Potential Market and Study Opportunities for HTG Transcriptome Panel Expands Potential Market and Study Opportunities for HTG Transcriptome Panel

HTG Completes HTP Product Next-Phase Development Milestone

Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in the Fields of Leukemia Research and Molecular Genetics Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in the Fields of Leukemia Research and Molecular Genetics

HTG Expands Therapeutics Scientific Advisory Board With Addition of Dr. Jerald Radich

The stock price of HTG Molecular Diagnostics Inc (NASDAQ: HTGM) increased by over 20% during intraday trading today. This is why it happened.

HTG Molecular Diagnostics Stock (HTGM): Why The Price Surged Today

HTG's Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies HTG's Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies

HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration

TUCSON, Ariz., Nov. 15, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that, on November 9, 2021 the Compensation Committee of the HTG Board of Directors granted inducement stock option awards to purchase an aggregate of 80,000 shares of common stock and 30,000 restricted stock unit awards (RSUs) to two employees who have recently joined HTG.

HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HTG Molecular Diagnostics' (HTGM) CEO John Lubniewski on Q3 2021 Results - Earnings Call Transcript

HTG Molecular Diagnostics (NASDAQ:HTGM) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.

Preview: HTG Molecular Diagnostics's Earnings

TUCSON, Ariz., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will participate in H.C. Wainwright's 23rd Annual Global Investment Conference, being held September 13th – 15th, 2021.

HTG Molecular Diagnostics to Present at H.C. Wainwright's 23rd Annual Global Investment Conference

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q2 2021 Results - Earnings Call Transcript

Call scheduled for today, August 12, at 4:30pm ET Call scheduled for today, August 12, at 4:30pm ET

HTG Molecular Diagnostics Reports Second Quarter 2021 Results

HTG Transcriptome Panel designed to measure approximately 20,000 mRNA targets using the  HTG EdgeSeq technology

HTG's New HTG Transcriptome Panel Launched with Commercial Availability in the U.S. and Europe

HTG Molecular Diagnostics Inc (NASDAQ: HTGM) has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe.  The company continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.

HTG Receives First Order For HTG Transcriptome Panel, Enters Two European EAP Agreements

The stock price of HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) increased by 7.34% yesterday. This is why it happened.

HTGM Stock Price: 7.34% Increase Explanation

TUCSON, Ariz., May 24, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that its HTG EdgeSeq technology is highlighted in several posters being presented at the American Society of Clinical Oncology (ASCO) conference, being held virtually from June 4-8, 2021.

HTG EdgeSeq Technology Highlighted in Several Posters Being Presented at the American Society of Clinical Oncology 2021 Virtual Conference

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q1 2021 Results - Earnings Call Transcript

Call scheduled for today, May 13, at 4:30 pm ET Call scheduled for today, May 13, at 4:30 pm ET

HTG Molecular Diagnostics Reports First Quarter 2021 Results and Provides a Corporate Update

TUCSON, Ariz., May 04, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter ended March 31, 2021 after the market close on Thursday, May 13, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13

TUCSON, Ariz., April 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021.

HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q4 2020 Results - Earnings Call Transcript

News for HTG Molecular Diagnostics Stock (HTGM)